MOXR0916

DRUG2 trials

Sponsors

Genentech, Inc.

Conditions

NeoplasmsUrothelial Carcinoma

Phase 1

A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors

CompletedNCT02219724

Genentech, Inc.Neoplasms

Start: 2014-08-12End: 2019-08-18Updated: 2020-02-05

Phase 2

A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy

TerminatedNCT03029832

Genentech, Inc.Urothelial Carcinoma

Start: 2017-04-27End: 2018-04-25Updated: 2019-05-31